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Peripheral T-cell lymphomas are a group of rare neoplasms originating from clonal proliferation
of mature post-thymic lymphocytes with different entities having specific biological characteristics
and clinical features. As natural killer cells are closely related to T-cells, natural killer-cell
lymphomas are also part of the group. The current World Health Organization classification
recognizes four categories of T/natural killer-cell lymphomas with respect to their presentation:
disseminated (leukemic), nodal, extranodal and cutaneous. Geographic variations in the distribution
of these diseases are well documented: nodal subtypes are more frequent in Europe and North
America, while extranodal forms, including natural killer-cell lymphomas, occur almost exclusively
in Asia and South America. On the whole, T-cell lymphomas are more common in Asia than in
western countries, usually affect adults, with a higher tendency in men, and, excluding a few
subtypes, usually have an aggressive course and poor prognosis. Apart from anaplastic lymphoma
kinase-positive anaplastic large cell lymphoma, that have a good outcome, other nodal and
extranodal forms have a 5-year overall survival of about 30%. According to the principal prognostic
indexes, the majority of patients are allocated to the unfavorable subset. In the past, the rarity of
these diseases prevented progress in the understanding of their biology and improvements in the
efficaciousness of therapy. Recently, international projects devoted to these diseases created networks
promoting investigations on T-cell lymphomas. These projects are the basis of forthcoming
cooperative, large scale trials to detail biologic characteristics of each sub-entity and to possibly
individuate targets for new therapies.
Keywords: Lymphoma, T-cell/epidemiology; Killer-cells, natural; Prognosis; Lymphoma, T- cell/
pathology; Lymphoma, T-Cell/classification; Hematologic neoplasms; South America; Europe
Introduction
T-cell Lymphomas constitute a heterogeneous group of rare disorders that have
different biological and clinical profiles resulting from clonal proliferation of mature
post-thymic lymphocytes, in the majority of the cases from either the CD8+ or CD4+
lineages. Most, therefore, express αβ T cell receptors. Since natural killer (NK) cells are
closely related to T-cells, neoplasms derived from these are also placed within this
group. Until the 1970s they were not distinguished from lymphomas originating from
the B-cell lineages but considered a major histologic subtype within a single group
that included all lymphomas that was only poorly described according to growth
pattern.(1) Only after the immune system was better characterized, lymphomas began
to be subdivided into B and T cell lineages and started to be considered separate
entities.(2-4) The role of the immunophenotype in distinguishing disease entities was
affirmed by the Revised European-American Lymphoma (REAL) classification published
in 1994(5) which was subsequently confirmed by the World Health Organization (WHO)
project.(6)
The 2008 WHO classification for hematopoietic malignancies(7) roughly divides the
mature forms of T-cell and NK-cell malignancies (otherwise reported as peripheral T-cell
lymphomas - PTCLs) into four categories according to their presentation: predominantly
leukemic (disseminated), nodal, extranodal and cutaneous. In each category, entities are
further differentiated based on morphologic, genotypic, genetic and immunohistochemical
criteria, as well as clinical behavior.(7)
Compared to B-cell lymphomas, mature T/NK-cell lymphomas are uncommon
malignancies accounting for 10 to 15% of all non-Hodgkin lymphomas (NHL), with
well documented geographic variations.(8-10) In the western hemisphere T-cell
lymphomas represent 5 to 10% of all NHL(8,11-13) with an overall incidence rate of 0.5-2
per 100,000 inhabitants per year.(14) Surveillance Epidemiology and End Results (SEER)
data (2004-2008)(15) report an age-adjusted incidence rate (IR) in the US for T/NK-cell
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lymphomas of 1.8/100,000 men and women per year. In
Europe, data from the Cancer Registry Based project on
Haematologic malignancies (HAEMACARE)(16) on lymphoid
malignancies diagnosed in 2000-2002 and archived in 44
European cancer registries present a crude IR of 1.13 per
100,000 inhabitants per year for mature T/NK-cell neoplasms.
Out of the 66371 cases diagnosed with a lymphoproliferative
disorder in the period 2000-2002, 2527 (3.8%) were mature
forms of T/NK-cell lymphoma. These patients can be
subdivided into two different categories, the first includes
cutaneous forms (n = 1208, IR = 0.54 per 100,000 inhabitants
per year) and the other grouping disseminated, nodal or
extranodal PTCLs (n = 1319, IR = 0.59 per 100,000 inhabitants
per year). These two categories have been investigated with
respect to survival confirming very different outcomes
for the two populations: period estimates for 2000-2002
of 5-year relative survival were calculated on a mean number
of 1046.5 cases of cutaneous PTCLs and 987.5 cases of other
T/NK-cell lymphomas leading to a 83.4% 5-year relative
survival for cutaneous PTCLs and a 38.6% 5-year relative
survival for non-cutaneous PTCLs.(17)
PTCLs are relatively more frequent in Asia(12,18,19) and
in Central and South America,(20-22) where approximately 15%
to 20% of lymphoma are diagnosed as PTCL or NK/T-cell
lymphomas, with NK-cell lymphomas (NKCL) occurring
almost exclusively in Asia and South America. The
differences in the geographic distribution of T-cell lymphoma
may result from a real higher incidence in eastern countries
as well as the relatively lower frequency in Asia of many
B-cell lymphomas such as follicular lymphoma.(23) Indeed,
race has been reported to correlate with the incidence of
B-cell lymphomas as they are more frequently detected in
Whites than in Asians, while the incidences for T-cell
lymphomas for Whites and Asians are comparable.(23) In
addition to race-linked factors, a possible cause of
geographic variations could be the higher prevalence of
viral infections, particularly the human T-cell lymphotropic
virus type 1 (HTLV-1) in eastern counties compared to
Europe and the US, an infection that appears to be related
to the onset of adult T-cell leukemia/lymphoma (ATLL) and
NK-cell neoplasms.(23-26)
The mature forms of T/NK-cell lymphomas usually
affect the adult population, with a median age between 55 to
60 years and a slight predominance in men.(13,14,27,28) Most of
the patients present with an advanced stage disease(11,13,27-
29) and constitutional symptoms(11,13,27) and a non-ambulatory
performance status in one third of the cases.(27,29)
PTCLs with cutaneous presentation may have a
relatively benign protracted course while nodal and
extranodal T-cell lymphomas have an aggressive clinical
behavior and poor prognosis. Indeed, with the exclusion of
anaplastic lymphoma kinase (ALK)-positive anaplastic large
cell lymphoma and indolent mycosis fungoides which have
good survival rates,(30) the prognosis of PTCLs is dismal
with a 5-year survival near to 30% on the whole.
Geographic distribution: the international
projects
The first attempt to systematically study the
distribution of NHL subtypes across geographic regions
based on collaborative international efforts was performed
after the NHL Classification Project was carried out.(31) The
project collected 1403 cases (diagnosed from 1988-1990)
from nine institutions in eight different geographic regions
thought to have a case base representative of their
geographical location. Out of the cases collected, upon a
review process involving five expert hematopathologists,
25 (1.8%) were found to have diagnoses other than NHL
and were excluded from the analysis and 1378 were
confirmed to be NHL. Analyses confirmed statistical
evidence that the distribution among the major histologic
subtypes of NHL differed substantially by geographical
region. According to the consensus diagnosis, a greater
percentage of follicular lymphoma was seen in North
America, London and Cape Town (28%-32%) than at the
other sites (8%-18%). PTCLs made up a higher percentage
of the cases from London (8%), Cape Town (8%) and Hong
Kong (10%) than from the other sites (1%-6%). Primary
mediastinal large B-cell lymphomas and mantle cell
lymphomas were more common in Locarno and Bellinzona
(9% and 14%, respectively) than at the other sites (0%-4%
and 1%-8%, respectively). Angiocentric nasal T/NK-cell
tumors were only seen in Hong Kong (8%) and, to a lesser
extent, in Lyon (2%).
The project included 129 cases (9.4% of 1378) of PTCLs,
33 of which were anaplastic large cell lymphomas (ALCLs:
2.4%).(12)
The frequencies of the 96 cases of non-anaplastic
PTCLs reported in the project varied geographically ranging
from 1.5% in Vancouver to 18.3% in Hong Kong.(8) According
to the consensus diagnosis, most of the 96 non-anaplastic
cases were reported as PTCL not otherwise specified (NOS)
(53 patients, 55%), followed by angiocentric nasal type (19
patients, 20%), which were almost exclusively recorded in
Hong Kong (16 cases), and angioimmunoblastic T-cell
lymphoma (AITL) (17 cases, 18%), whereas the other
subtypes were rare.
Later on, the International T-cell Lymphoma Project
(ITLP) collected 1314 cases of T/NK-cell lymphomas from
22 Institutions worldwide(28) with diagnoses made from 1990-
2002. The results confirm those reported by the NHL
Classification Project with respect to the geographical
distribution of subtypes: higher rates of leukemic and NK-
cell neoplasms were recorded in Asia (25% and 22.4%,
respectively) than in North America (2% and 5.1%,
respectively) and in Europe (1% and 4.3%, respectively).
On the other hand, PTCL-NOS were more frequent in both
North America and Europe (34.4% and 34.3%, respectively)
than in Asia (22.4%). ALK-positive ALCLs were most
common in North America (16%) whereas the enteropathy
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subtype was most common in Europe (9.1%). Notably, AITL
were reported to be more common in Europe (28.7%)
compared to North America (16%) and Asia (17.9%). With
respect to rarer extranodal forms (excluding primary
cutaneous ALCL), most of the cases were diagnosed in
Europe (2.8%) and only a few cases were reported in North
America and Asia (1.6% and 1.5%, respectively).
More recently the ITLP launched the T-Cell Project, a
study aimed at investigating clinical and biological
characteristics of aggressive nodal and extranodal PTCLs
by means of prospective data collection. An overview of
the study is described elsewhere.(32,33) The study started
enrolling patients at the end of 2006 and so far 790 patients
have been registered from 63 Institutions distributed in
four different geographic regions: Europe (Italy: 38 sites;
UK: 4; Switzerland: 3; Slovakia: 1; Spain: 1), United States
(Memorial Sloan-Kettering Cancer Center, M. D. Anderson
Cancer Center, University of Nebraska Medical University,
Stamford University, Cleveland Clinic Foundation, Fred
Hutchinson Cancer Research Center), South America (Ar-
gentina: 3 sites; Brazil: 2; Chile: 1; Uruguay: 1) and the
Middle/Far East (South Korea: 1; Hong Kong: 1; Israel: 1)
with total patients of 338, 136, 170 and 146, respectively.
Four additional sites recently joined the project, but up to
now no patients have been registered. The preliminary
analysis of the first 524 patients included in the T-Cell
Project and presented at the 11th International Conference
on Malignant Lymphoma in Lugano(34) supports the
previously described geographical variations for these
disorders.
At present, 755 patients have been validated in the
study. Out of these, 18 were considered after review as
misdiagnosed by the local pathologist and were excluded.
Out of the remaining 737 patients, PTCLs-NOS account
for 285 cases (38.7%) and AITL for only 127 cases (17.2%);
on the other hand, 94 (12.7%) cases of ALK-negative
ALCL were registered. The AITL and ALK-negative ALCL
cohorts are about half and twice, respectively of what
was expected. The distribution of cases for the whole
population according to histologic subtypes is
summarized in Table 1.
Table 2 shows the distribution of histologic entities
by geographic region according to reviewed diagnosis.
PTCLs-NOS represent the most common subtype in
Europe, North America and South America (40%, 42% and
42%, respectively), whereas NKCL is the most common
subtype in Asia (31%). Both ALK-negative and ALK-
positive ALCLs are prevalent in South America (23% and
8%, respectively).
Europe
So far, the European cohort of the T-Cell Project
includes 317 validated cases. The overall distributions of
histologic subtypes in the European countries - Italy, UK
and others counties (Switzerland, Slovakia and Spain,
grouped together) – are presented in Table 3. About three
quarters of the European patients have been diagnosed
with PTCLs-NOS (40%), AITL (20%) or ALK-negative
ALCLs (14%).
Table 3 shows that significant differences between
countries are evident. ALK-negative ALCL is the most
common subtype in the UK (20%) and rarely diagnosed
in Switzerland, Slovakia and Spain. In Italy they represent
14% of the cases and are less frequent than their ALK-
positive counterpart (8%); Italy has the highest rate for
this subtype. Extranodal forms of PTCLs reported in
Europe have singular distributions for all countries: the
majority of NKCL and enteropathy-type PTCL (11% in
both cases) and two out of three cases of gamma/delta
peripheral PTCL were registered in Switzerland, Slovakia
and Spain, while three out of the four European cases of
subcutaneous panniculitis-like PTCL were diagnosed in
Italy.
Clinical characteristics of patients registered by
European sites are summarized in Table 4.
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South America
At present, 152 patients from South American
countries were registered in the T-Cell Project. The overall
distribution and the distribution by country – Chile, Brazil
and Argentina/Uruguay – of different histologic entities
are shown in Table 5.
As expected, the rate of PTCLs-NOS is similar to that
of Europe (42%) and the percentages of ALK-negative
ALCL and of NKCL are higher than in Europe (23% and
13%, respectively). Considering the distribution by country,
the PTCL-NOS rate ranges from 19% in Brazil to 51% in
other countries. Relative high rates of both ALK-negative
(23%) and ALK-positive (8%) ALCLs have been registered
in this area compared to Europe. The highest rate of ALK-
negative ALCL was recorded in Brazil with 39% of cases,
while in Argentina/Uruguay the percentage (11%) is lower
than the mean value of South America for this subtype.
Similarly, the highest rate of ALK-positive ALCLs (12%)
was reported in Brazil. The rate of NKCLs in South America
is on the whole double of that in Europe at 15% in both
Brazil and Argentina/Uruguay. Interestingly, no extranodal
forms of PTCLs other than NKCL were reported for Brazil,
while these forms are more common in Chile; the only case
of enteropathy-type PTCL and five out of the six cases of
subcutaneous panniculitis-like PTCL were diagnosed in
this country.
Of note, AITL is confirmed as a rare subtype in this
geographic region accounting for a maximum of 10% of
cases registered in Brazil.
Clinical characteristics of patients registered by South
American sites are summarized in Table 6.
T-Cell Lymphomas in South America and Europe
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In conclusion the preliminary data coming from the
T-Cell Project confirm the characteristic and peculiar profiles
for Europe and South America in the distribution of all
subtypes of aggressive PTCLs except PTCL-NOS. AITL is
confirmed as a distinctive disorder in Europe, while in South
America, NKCL and ALK-negative ALCL represent the most
common subtypes.
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